We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.145 | 0.29% | 49.475 | 49.47 | 49.48 | 49.60 | 49.3481 | 49.42 | 195,677 | 15:07:01 |
From May 2022 to May 2024
By Adria Calatayud
Sanofi SA said the U.S. Food and Drug Administration has approved its Altuviiio drug, a once weekly treatment for hemophilia A.
The French pharmaceutical company said this is the first approval of the drug, previously referred to as efanesoctocog alfa, and that regulatory submission in the European Union is expected in the second half of this year.
The FDA had granted priority review to the drug in August and designed it a breakthrough therapy in May.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
February 24, 2023 01:18 ET (06:18 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
